https://mindmedicinelaw.com/briefing/trump-executive-order-fast-tracks-psilocybin-ibogaine-access-in-us-20261030-55162The Psychedelic Journalen2026-10-31T15:05:54.050372+00:00Trump Executive Order Fast-Tracks Psilocybin, Ibogaine Access in USpsilocybin policy, ibogaine regulation, executive order psychedelics, federal psychedelic law, mental health innovation, clinical trial acceleration, controlled substances act, public health policy, psychedelic therapy accesshttps://mindmedicinelaw.com/briefing/bridging-efficacy-and-real-world-practice-in-psychedelic-trials-20261030-55107The Psychedelic Journalen2026-10-30T22:05:37.144623+00:00Bridging Efficacy and Real-World Practice in Psychedelic Trialspsychedelic clinical trials, real-world effectiveness, psilocybin therapy, mdma-assisted therapy, fda regulation, payer adoption, implementation science, oregon psilocybin program, integration support, trial designhttps://mindmedicinelaw.com/briefing/tryptophan-metabolism-gut-brain-axis-and-depression-implications-for-psychedelic-20261029-55163The Psychedelic Journalen2026-10-31T15:07:57.891677+00:00Tryptophan Metabolism, Gut–Brain Axis, and Depression: Implications for Psychedelic Researchtryptophan metabolism, gut-brain axis, depression heterogeneity, serotonin pathways, psychedelic research, multi-omics biomarkers, microbiome interventions, precision psychiatry, clinical trial designhttps://mindmedicinelaw.com/briefing/hhs-proposes-overhaul-of-federal-urine-drug-testing-guidelines-20261029-55141The Psychedelic Journalen2026-10-31T15:07:19.926218+00:00HHS Proposes Overhaul of Federal Urine Drug Testing Guidelinesfederal drug testing, HHS guidelines, psychedelics policy, psilocybin, MDMA, workplace compliance, clinical research risk, federal employment law, public health policyhttps://mindmedicinelaw.com/briefing/psilocybin-in-aud-and-depression-cognitive-and-clinical-effects-in-pilot-rct-20261029-55165The Psychedelic Journalen2026-10-31T15:07:04.963435+00:00Psilocybin in AUD and Depression: Cognitive and Clinical Effects in Pilot RCTpsilocybin, alcohol use disorder, major depressive disorder, cognitive flexibility, cognitive stability, randomized controlled trial, mechanism of action, pilot study, clinical outcomes, psychedelic therapyhttps://mindmedicinelaw.com/briefing/sv2a-synaptic-density-and-depression-chronicity-not-severity-drives-biomarker-si-20261029-55197The Psychedelic Journalen2026-10-31T15:06:51.115000+00:00SV2A Synaptic Density and Depression: Chronicity, Not Severity, Drives Biomarker Signalsv2a, synaptic density, major depressive disorder, biomarkers, pet imaging, psychedelic research, clinical trial endpoints, regulatory strategy, depression chronicityhttps://mindmedicinelaw.com/briefing/hhs-proposes-revisions-to-federal-oral-fluid-drug-testing-guidelines-20261029-55142The Psychedelic Journalen2026-10-31T15:06:36.653601+00:00HHS Proposes Revisions to Federal Oral Fluid Drug Testing Guidelineshhs, oral fluid drug testing, federal workplace, psychedelics, clinical trial risks, employment law, detection windows, policy update, safety-sensitive positionshttps://mindmedicinelaw.com/briefing/nanomolar-dmt-detection-field-effect-sensor-breakthrough-for-clinical-and-public-20261029-55201The Psychedelic Journalen2026-10-31T15:06:21.639919+00:00Nanomolar DMT Detection: Field-Effect Sensor Breakthrough for Clinical and Public Health Usedmt detection, field-effect transistor sensor, psychedelic biomarkers, clinical trial monitoring, public health surveillance, chemical activation, point-of-care testing, regulatory compliance, nanomolar sensitivityhttps://mindmedicinelaw.com/briefing/psilocybin-s-multi-scale-brain-effects-in-macaques-translational-insights-20261029-55028The Psychedelic Journalen2026-10-30T22:07:12.002799+00:00Psilocybin’s Multi-Scale Brain Effects in Macaques: Translational Insightspsilocybin, non-human primate research, macaque brain, translational neuroscience, clinical trial design, fda regulatory review, neuroimaging, preclinical models, psychedelic safetyhttps://mindmedicinelaw.com/briefing/psychedelics-and-disorders-of-consciousness-trial-design-challenges-in-the-us-an-20261029-55106The Psychedelic Journalen2026-10-30T22:06:57.926373+00:00Psychedelics and Disorders of Consciousness: Trial Design Challenges in the US and EUpsychedelic clinical trials, disorders of consciousness, trial design challenges, fda guidance, surrogate consent, neuroimaging endpoints, ethical issues, regulatory barriers, psilocybin research, dmt trialshttps://mindmedicinelaw.com/briefing/virtual-reality-integration-in-ketamine-therapy-us-chart-review-insights-20261029-55109The Psychedelic Journalen2026-10-30T22:06:40.576721+00:00Virtual Reality Integration in Ketamine Therapy: US Chart Review Insightsvirtual reality, ketamine therapy, psychedelic-assisted therapy, digital therapeutics, retrospective chart review, clinical protocols, FDA regulation, tolerability, mental health innovationhttps://mindmedicinelaw.com/briefing/psychedelics-for-substance-use-disorders-evidence-mechanisms-and-gaps-20261029-55027The Psychedelic Journalen2026-10-30T22:05:52.342207+00:00Psychedelics for Substance Use Disorders: Evidence, Mechanisms, and Gapspsychedelics, substance use disorder, psilocybin, clinical trials, neuroplasticity, ibogaine, ketamine, addiction treatment, policy, mechanismshttps://mindmedicinelaw.com/briefing/deep-brain-stimulation-for-anorexia-nervosa-efficacy-targets-and-challenges-20261028-55031The Psychedelic Journalen2026-10-30T22:07:42.964765+00:00Deep Brain Stimulation for Anorexia Nervosa: Efficacy, Targets, and Challengesdeep brain stimulation, anorexia nervosa, treatment-resistant, neuroanatomical targets, connectome-guided neuromodulation, clinical trials, ethical challenges, ai-assisted neuromodulation, device regulationhttps://mindmedicinelaw.com/briefing/torpor-depression-link-implications-for-neuroscience-and-trials-20261028-55046The Psychedelic Journalen2026-10-30T22:07:27.792988+00:00Torpor-Depression Link: Implications for Neuroscience and Trialstorpor, depressive disorders, animal models, clinical trial design, psychedelic research, circadian biology, neuroplasticity, translational neuroscience, biomarkers, regulatory implicationshttps://mindmedicinelaw.com/briefing/controlled-vs-naturalistic-dosing-in-cannabis-research-evolving-standards-20261028-54914The Psychedelic Journalen2026-10-30T15:06:10.409021+00:00Controlled vs. Naturalistic Dosing in Cannabis Research: Evolving Standardscannabis research, controlled dosing, naturalistic studies, clinical trial design, regulatory science, public health policy, thc potency, hybrid study methods, fda guidance, market regulationhttps://mindmedicinelaw.com/briefing/mdma-enhanced-exposure-therapy-trial-in-u-s-va-outpatient-care-20261027-55184The Psychedelic Journalen2026-10-31T15:06:07.603869+00:00MDMA-Enhanced Exposure Therapy Trial in U.S. VA Outpatient Caremdma-assisted therapy, ptsd, veterans affairs, clinical trial design, exposure therapy, telehealth, masking integrity, psychedelic research, policy implicationshttps://mindmedicinelaw.com/briefing/low-dose-ketamine-modulates-brain-entropy-in-trd-neuroimaging-evidence-20261026-55055The Psychedelic Journalen2026-10-30T22:06:08.114135+00:00Low-Dose Ketamine Modulates Brain Entropy in TRD: Neuroimaging Evidenceketamine, brain entropy, treatment-resistant depression, neuroimaging, biomarkers, psychedelic therapy, clinical trials, mechanism of action, rapid antidepressant, translational neurosciencehttps://mindmedicinelaw.com/briefing/india-s-first-public-interventional-psychiatry-service-integrates-psychedelic-th-20261023-55001The Psychedelic Journalen2026-10-30T22:06:25.460169+00:00India’s First Public Interventional Psychiatry Service Integrates Psychedelic Therapiesinterventional psychiatry, psychedelic therapy, india public health, neuromodulation, teaching hospital, clinical integration, regulatory policy, mental health innovation, low- and middle-income countrieshttps://mindmedicinelaw.com/briefing/psilocybin-s-biological-effects-in-parkinson-s-early-clinical-trial-insights-20261021-54989The Psychedelic Journalen2026-10-30T15:05:52.728632+00:00Psilocybin’s Biological Effects in Parkinson’s: Early Clinical Trial Insightspsilocybin, parkinson's disease, inflammation markers, mitochondrial stress, clinical trial, neurodegeneration, biomarkers, policy implications, mechanistic researchhttps://mindmedicinelaw.com/briefing/ketamine-and-buprenorphine-for-suicidal-crisis-u-s-clinical-implications-20261019-55270The Psychedelic Journalen2026-10-31T15:07:46.057668+00:00Ketamine and Buprenorphine for Suicidal Crisis: U.S. Clinical Implicationsketamine, buprenorphine, suicidal crisis, psychiatric care, clinical trials, policy implications, rapid-acting antidepressants, safety concerns, outpatient transition, mental health protocolshttps://mindmedicinelaw.com/briefing/sex-specific-cognitive-effects-of-lsd-microdosing-policy-and-research-implicatio-20261019-55269The Psychedelic Journalen2026-10-31T15:07:31.864565+00:00Sex-Specific Cognitive Effects of LSD Microdosing: Policy and Research Implicationslsd microdosing, sex differences, cognitive benefits, psychedelic research, clinical trial design, regulatory policy, public health, women's health, neuroscience, personalized medicine